# US 2019/0336588 A1 · Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0336588 A1
- Document ID: US20190336588A1
- Status: Published application
- Kind: A1
- Application number: 16/322,837
- Filed: 2017-08-04
- Published: 2019-11-07
- Earliest claimed: 2016-08-04
- Assignees: Baxalta Incorporated
- Applicants: Baxalta Incorporated; Baxalta GmbH
- Inventors: Bruce EWENSTEIN; Brahm GOLDSTEIN; Bernhard MAJER; Paolo ROSSATO; Friedrich SCHEIFLINGER; Marietta TURECEK
- Web page: https://patentgrep.com/patent/US20190336588A1

## CPC

- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.

## Claims

### Claim 1

A method for treating or preventing a vaso-occlusive crisis in a subject suffering from sickle cell disease, the method comprising administering to the subject in need thereof a therapeutically effective amount of a composition comprising A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13).

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is administered ADAMTS13 after symptoms of a vaso-occlusive crisis are present.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is administered ADAMTS13 before symptoms of a vaso-occlusive crisis are present.

### Claim 4 (depends on 1)

The method of claim 1, wherein administering ADAMTS13 reduces at least one of inflammation, vasoconstriction, platelet aggregation, or a combination of any thereof as compared to control or without treatment.

### Claim 5 (depends on 1)

The method of claim 1, wherein administering ADAMTS13 results in at least one of improved survival, improved lung function, reduced organ damage, reduced pulmonary vascular leakage, or a combination of any thereof as compared to control or without treatment.

### Claim 6 (depends on 1)

The method of claim 1, wherein administering ADAMTS13 reduces and/or prevents at least one of impaired blood flow, blood coagulation, vascular inflammation, thrombosis, ischemic cell damage, or organ damage, or a combination of any thereof as compared to control or without treatment.

### Claim 7 (depends on 1)

The method of claim 1, wherein administering ADAMTS13 reduces and/or prevents pain or severity of the pain as compared to control or without treatment.

### Claim 8 (depends on 1)

The method of claim 1, wherein administering ADAMTS13 reduces the frequency of occurrence of VOC and/or duration of VOC episodes as compared to without treatment.

### Claim 9 (depends on 1)

The method of claim 1, wherein administering ADAMTS13 reduces expression, level, and/or activation of at least one of VCAM-1, ICAM-1, P-NF-kB, NF-kB, ET-1, TXAS, and HO-1 in an organ as compared to control or without treatment.

### Claim 10 (depends on 1)

The method of claim 1, wherein administering ADAMTS13 increases the level of at least one of Hct, Hb, MCV, and MCH in the blood as compared to control or without treatment.

### Claim 11 (depends on 1)

The method of claim 1, wherein administering ADAMTS13 reduced the level of at least one of CHCM, HDW, LDH, and neutrophil numbers in the blood as compared to control or without treatment.

### Claim 12 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of ADAMTS13 is from about 20 to about 6,000 international units per kilogram body weight, about 40 to about 4,000 international units per kilogram body weight, about 50 to about 3,000 international units per kilogram body weight, or 50 to about 500 international units per kilogram body weight.

### Claim at position 13

-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the composition comprising ADAMTS13 is administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, daily, every 12 hours, every eight hours, every six hours, every four hours, or every two hours.

### Claim 17 (depends on 1)

The method of claim 1, wherein the composition comprising ADAMTS13 is administered intravenously or subcutaneously.

### Claim 18 (depends on 1)

The method of claim 1, wherein the ADAMTS13 is recombinant ADAMTS13.

### Claim 19 (depends on 1)

The method of claim 1, wherein the ADAMTS13 is plasma derived.

### Claim 20 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 21 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 22 (depends on 1)

The method of claim 1, wherein the composition is in a stable aqueous solution ready for administration.

### Claim 23 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the composition comprising ADAMTS13 is administered to the subject within 48 hours after the onset of the vaso-occlusive crisis.

### Claim 24 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the composition comprising ADAMTS13 for preventing the vaso-occlusive crisis is sufficient to maintain an effective level of ADAMTS13 activity in the subject.

### Claim at position 23

-26. (canceled)

### Claim 27

A method for treating, ameliorating, or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), the method comprising administering to the subject in need thereof a therapeutically effective amount of a composition comprising A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13).

### Claim 28 (depends on 27)

The method of claim 27, wherein the subject suffers from a condition or a combination of the conditions selected from the group consisting of inflammatory pulmonary edema, inflammatory pulmonary infiltrates, impaired oxygenation, and hypoxemia.

### Claim 29 (depends on 27)

The method of claim 27, wherein administering ADAMTS13 results in at least one of improved survival, improved lung function, reduced organ damage, reduced pulmonary vascular leakage, or a combination of any thereof as compared to control or without treatment.

### Claim 30 (depends on 27)

The method of claim 27, wherein administering ADAMTS13 reduces at least one of inflammation, vasoconstriction, platelet aggregation, or a combination of any thereof as compared to control or without treatment.

### Claim 31 (depends on 27)

The method of claim 27 damage, organ damage, or a combination of any thereof as compared to control or without treatment.

### Claim 32 (depends on 27)

The method of claim 27, wherein administering ADAMTS13 reduces and/or prevents pain or severity of the pain as compared to control or without treatment.

### Claim 33 (depends on 27)

The method of claim 27, wherein administering ADAMTS13 reduces the frequency of occurrence of ALI and/or ARDS and/or duration of ALI and/or ARDS episodes as compared to without treatment.

### Claim at position 31

-47. (canceled)

### Claim 48 (depends on 27)

The method of claim 27, wherein the therapeutically effective amount of the composition comprising ADAMTS13 is administered to the subject within 48 hours after the detection of inflammatory pulmonary edema, inflammatory pulmonary infiltrates, impaired oxygenation, or hypoxemia.

### Claim 49 (depends on 27)

The method of claim 27, wherein the therapeutically effective amount of the composition comprising ADAMTS13 for treating, ameliorating, or preventing lung injury is sufficient to maintain an effective circulating level of ADAMTS13 activity in the subject.

### Claim at position 34

-51. (canceled)
